A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
In the register
The register attaches this trial to Bimatoprost (scalp) (AbbVie), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Allergan
- Participants (registry)
- 244
- Start
- August 2013
- Primary completion
- September 2014
- Study completion
- January 2015
- Last registry update
- March 2016
- Countries
- United States
Conditions studied: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
Other trials of Bimatoprost (scalp)
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.